Lumen gets $16M for C. diff drug; Flashpoint’s seed round; Amplifier expands Series A

2023-10-17

IPO

Plus, Tessellate BIO, led by former Big Pharma execs, comes out of stealth. Lumen Bioscience gets $16M to advance C. diff therapy: The Department of Defense awarded $16.2 million to the Seattle-based company, which is developing an oral drug to treat and prevent infections with C. difficile . It plans to start enrolling 375 patients in a late-stage trial for LMN-201 by the end of the year. Flashpoint’s $10M: Flashpoint Therapeutics on Tuesday announced a $10 million seed round, led by Riyadh-based Beta Lab. The funds are expected to help advance the company’s first cancer therapy and select a second candidate. Flashpoint’s platform is based on work out of Chad Mirkin’s lab at Northwestern University’s International Institute for Nanotechnology.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构